Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.

Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL.

Gut. 2015 Apr;64(4):667-72. doi: 10.1136/gutjnl-2014-307237. Epub 2014 May 15.

PMID:
24833635
2.

Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.

Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM.

Clin Gastroenterol Hepatol. 2015 Nov;13(11):1984-92.e1. doi: 10.1016/j.cgh.2015.06.002. Epub 2015 Jun 12.

PMID:
26073492
3.

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.

Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N, Lee DH.

Korean J Hepatol. 2011 Dec;17(4):268-73. doi: 10.3350/kjhep.2011.17.4.268.

4.

Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.

Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF.

J Gastroenterol Hepatol. 2014 May;29(5):1028-34. doi: 10.1111/jgh.12476.

PMID:
24325451
5.

Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.

Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH.

Int J Infect Dis. 2016 Feb;43:43-48. doi: 10.1016/j.ijid.2015.10.019. Epub 2015 Oct 30.

6.

Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.

Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E.

J Hepatol. 2014 Jan;60(1):62-8. doi: 10.1016/j.jhep.2013.08.023. Epub 2013 Sep 6.

PMID:
24012614
7.

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.

Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.

J Viral Hepat. 2012 Oct;19(10):724-31. doi: 10.1111/j.1365-2893.2012.01599.x. Epub 2012 Mar 15.

PMID:
22967104
8.

Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients.

Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF.

Hepatology. 2013 Dec;58(6):1888-96. doi: 10.1002/hep.26549. Epub 2013 Oct 17.

PMID:
23744454
9.

Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.

Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.

Am J Gastroenterol. 2011 Oct;106(10):1766-73. doi: 10.1038/ajg.2011.253. Epub 2011 Aug 9.

PMID:
21826112
10.

Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.

He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y.

BMC Infect Dis. 2013 Oct 3;13:458. doi: 10.1186/1471-2334-13-458.

11.

Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.

Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA, Peng J.

J Infect Dis. 2017 Feb 15;215(4):581-589. doi: 10.1093/infdis/jix025.

PMID:
28329347
12.

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.

Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF.

J Hepatol. 2013 Oct;59(4):709-16. doi: 10.1016/j.jhep.2013.06.007. Epub 2013 Jun 17.

PMID:
23792029
13.

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.

Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF.

Hepatology. 2013 Sep;58(3):923-31. doi: 10.1002/hep.26376. Epub 2013 Jul 24.

PMID:
23468172
14.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
15.

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.

Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ.

Gut. 2014 Aug;63(8):1325-32. doi: 10.1136/gutjnl-2013-305517. Epub 2013 Oct 25.

PMID:
24162593
16.

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW.

J Med Virol. 2011 Jul;83(7):1178-86. doi: 10.1002/jmv.22089.

PMID:
21567421
17.

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B.

Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY.

J Viral Hepat. 2012 Feb;19(2):e41-7. doi: 10.1111/j.1365-2893.2011.01509.x. Epub 2011 Nov 20.

PMID:
22239525
18.

Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.

Jung KS, Park JY, Chon YE, Kim HS, Kang W, Kim BK, Kim SU, Kim do Y, Han KH, Ahn SH.

J Gastroenterol. 2016 Aug;51(8):830-9. doi: 10.1007/s00535-015-1153-1. Epub 2015 Dec 19.

PMID:
26687058
19.

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients.

Wang CC, Tseng TC, Wang PC, Lin HH, Kao JH.

J Formos Med Assoc. 2014 Nov;113(11):786-93. doi: 10.1016/j.jfma.2013.06.003. Epub 2013 Aug 1.

20.

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.

Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C.

J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28.

PMID:
25176615

Supplemental Content

Support Center